New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline setbacks.

Its dermatitis drug could win at least 10% of annual sales in dermatitis by 2030—or about $3 billion.

Major U.S. equities indexes were mixed in the final session of the holiday-shortened trading week as President Donald Trump reverted to an antagonistic tone on trade with China and the latest Perso...

Regeneron's stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after analysts had just placed a high probability of a positive result.

Regeneron shares fell nearly 13% before the bell on Friday after its experimental drug for patients with a type of lung condition commonly called "smoker's lung" failed a late-stage trial, although...

Earlier this year, biotech company 23andMe filed for bankruptcy. The harsh reality was that its business, while enticing to people who wanted to learn about their backgrounds via DNA testing kits, ...

REGN posts strong early data for linvoseltamab combos in relapsed/refractory multiple myeloma, with ORRs up to 90% and high complete response rates.

Regeneron is set to acquire 23andMe assets for $256 million to boost genetic drug discovery. The transaction is expected to close by third-quarter 2025.

It will acquire genetic data of more than 15 million customers – raising privacy concerns from individuals who had willingly handed over the samples to completely different owners.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has agreed to buy genetic testing company 23andMe for $256 million, two months after the biotech firm filed for Chapter 11 bankruptcy. The deal includes ...

Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during t...

Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports first-quarter results on April 29.

Regeneron Pharmaceuticals said on Tuesday it had entered into a deal valued at more than $3 billion with contract drug developer Fujifilm Diosynth to expand its U.S. manufacturing capacity.

TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response le...